Vimarsana
Biggest News Aggregation in the World

Page 48 - Thomas Triomphe News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Thomas Triomphe. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Thomas Triomphe Today - Breaking & Trending Today

COVID-19: Sanofi, GSK say vaccine shows positive results - Vimarsana News

COVID-19: Sanofi, GSK say vaccine shows positive results

French pharmaceuticals giant Sanofi SA and the UK’s GlaxoSmithKline PLC yesterday reported “strong immune responses” in early tests of their COVID-19 vaccine, raising hopes it could join the fight against the pandemic. The companies said the results of the phase 2 study would enable them to move to a late-stage trial in the coming weeks — a reversal of fortune after their research was dealt a setback late last year. The experimental vaccine “achieved strong rates of neutralizing antibody responses, in line with those measured in people who have recovered from COVID-19, in all adult a...

GlaxoSmithKline PLC and Sanofi plan to join vaccine race with booster doses - Vimarsana News

GlaxoSmithKline PLC and Sanofi plan to join vaccine race with booster doses

GSK and Sanofi look to catch up in vaccine race with booster doses Approval may come a year later after their competitors, but the pair reckon there is a need for their candidate GlaxoSmithKline PLC (LON:GSK) and Sanofi are planning to join the vaccine race well after their competitors as they pin their hopes on the need for boosters. The pair have received lukewarm market reaction despite posting positive mid-stage trial results for their COVID-19 vaccine. The FTSE 100 pharma company was flat on Monday as investors are likely waiting for phase 3 numbers before popping the champagne open. The...

Sanofi-Glaxo Covid vaccine works well in re-test, expects clearance by end of 2021 - Vimarsana News

Sanofi-Glaxo Covid vaccine works well in re-test, expects clearance by end of 2021

Sanofi-Glaxo Covid vaccine works well in re-test, expects clearance by end of 2021 Suzi Ring © Provided by The Print London: Sanofi and GlaxoSmithKline Plc reported positive results from a redo of a mid-stage study for their Covid-19 vaccine, putting the delayed shot on track for possible clearance by the end of the year. Volunteers showed a similar immune response to people who have recovered from the coronavirus, Sanofi said Monday. Those who’d already been infected had a higher response after just one injection, prompting the companies to decide to test a second formula...

Source: msn.com
Sanofi and GlaxoSmithKline report positive results from Phase 2 vaccine trial - Vimarsana News

Sanofi and GlaxoSmithKline report positive results from Phase 2 vaccine trial

Sanofi and GlaxoSmithKline report positive results from Phase 2 vaccine trial From CNN Health’s Naomi Thomas French and British pharmaceutical giants Sanofi and GlaxoSmithKline’s Covid-19 vaccine candidate showed a strong immune response in adults ages 18 to 95 and no safety concerns in its Phase 2 trial, the companies said in a news release Monday. A large Phase 3 trial of the vaccine is expected to begin in the coming weeks, they said. The trial enrolled 722 volunteers in the United States and Honduras who received two injections 21 days apart and at three different dose levels. The co...

Source: cnn.com
Sanofi, GlaxoSmithKline (GanoxSmithKline) will start Phase 3 trials of COVID-19 vaccine after early setbacks - Vimarsana News

Sanofi, GlaxoSmithKline (GanoxSmithKline) will start Phase 3 trials of COVID-19 vaccine after early setbacks

Sanofi, GlaxoSmithKline (GanoxSmithKline) will start Phase 3 trials of COVID-19 vaccine after early setbacks The two companies announced on Monday that a COVID-19 vaccine jointly developed by Sanofi and GlaxoSmithKline has shown a strong immune response in early clinical trial results, allowing it to enter late-stage research. France’s Sanofi and Britain’s GlaxoSmithKline (GSK) said a global Phase 3 trial will begin in the next few weeks, involving more than 35,000 adults. The goal is that the vaccine will be approved in the fourth quarter before it is initially hit in the first half of t...